Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
van Cruijsen H et al. - In a study to assess the possible association of ganglioside GM3 expression and signal transducer and activator of transcription (STAT)-3 activation with suppression of dendritic cell (DC) activation and angiogenesis in non-small cell lung cancer (NSCLC), it was shown that N-glycolyl GM3 (GM3) and phosphorylated STAT3 (pSTAT3) are widely expressed in NSCLC. Based on CD83 expression, GM3, but not pSTAT3, appeared to be involved in tumor-induced DC suppression. pSTAT3 expression was not associated with microvessel density (MVD), while GM3 might play an anti-angiogenic role.
Methods- Immunohistochemistry was performed on a tissue array to determine GM3 and pSTAT3 expression in 176 primary NSCLC resections.
- Median values of GM3 and pSTAT3 expression were used as cut off.
- MVD was determined by CD34 staining and morphology.
- CD1a and CD83 were used to determine infiltrating immature and mature dendritic cells, respectively.
- 94% and 71% of the NSCLC samples expressed GM3 and nuclear pSTAT3, respectively.
- Median overall survival was 40.0 mos.
- Both low GM3 expression and high pSTAT3 expression were associated with worse survival, which reached near significance for GM3.
- MVD, determined by CD34 staining and morphology, was lower in NSCLC samples with high GM3 expression.
- CD1a+ cells (immature DCs) were more frequent in NSCLC tissues vs peritumoral lung tissue, while CD83+ cells (mature DCs) were more frequent in peritumoral lung tissue.
- CD83+ DCs were less frequent in NSCLC tissues with high GM3 expression.
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Polymorphisms in the CASPASE Genes and Survival in Patients With Early-Stage Non-Small-Cell Lung Cancer
Journal of Clinical Oncology, 10/16/09
Absence of inflammation and pneumonia during infection with non-pigmented Yersinia pestis reveals new role for the pgm locus in pathogenesis
Infection and Immunity, 10/30/09
Association and interaction analyses of eight genes under asthma linkage peaks
Allergy, 10/15/09
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/09
Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer
Annals of Oncology, 10/19/09
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase III study
The Lancet, 10/26/09
Sponsor
Article Search
Sponsor


See Latest Articles


